消除脑膜炎球菌病的前景。
Prospects for eradication of meningococcal disease.
机构信息
Department of Paediatric Intensive Care, St Marys Hospital, Praed Street, London, UK.
出版信息
Arch Dis Child. 2012 Nov;97(11):993-8. doi: 10.1136/archdischild-2012-302036. Epub 2012 Sep 15.
Abstract
Meningococcal meningitis and septicaemia remain a serious global health threat. This review focuses on the epidemiology of meningococcal disease following the recent implementation of effective vaccines and the potential utility of a vaccine against serogroup B meningococcus.
摘要
脑膜炎球菌性脑膜炎和败血症仍然是一个严重的全球健康威胁。本综述重点讨论了最近实施有效疫苗后脑膜炎球菌病的流行病学，以及针对 B 群脑膜炎球菌的疫苗的潜在效用。
相似文献
1
Prospects for eradication of meningococcal disease.消除脑膜炎球菌病的前景。
Arch Dis Child. 2012 Nov;97(11):993-8. doi: 10.1136/archdischild-2012-302036. Epub 2012 Sep 15.
2
Meningococcal vaccines in China.中国的脑膜炎球菌疫苗。
Hum Vaccin Immunother. 2021 Jul 3;17(7):2197-2204. doi: 10.1080/21645515.2020.1857201. Epub 2021 Feb 10.
3
Authors' response: Meningococcal vaccine antigen diversity in global databases.作者回复：全球数据库中的脑膜炎球菌疫苗抗原多样性。
Euro Surveill. 2016 Apr 14;21(15). doi: 10.2807/1560-7917.ES.2016.21.15.30192.
4
Meningococcal serogroup B outbreaks and use of 4CMenB vaccine.B群脑膜炎球菌暴发与4CMenB疫苗的使用
J Am Pharm Assoc (2003). 2014 Mar-Apr;54(2):198-201. doi: 10.1331/JAPhA.2014.14512.
5
[Health Technology Assessment of meningococcal B vaccine (Trumenba) in adolescent in Italy].[意大利青少年群体中B型脑膜炎球菌疫苗（Trumenba）的卫生技术评估]
J Prev Med Hyg. 2019 Dec 19;60(3 Suppl 2):E1-E94. doi: 10.15167/2421-4248/jpmh2019.60.3s2. eCollection 2019 Dec.
6
Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.消除非洲脑膜炎带的脑膜炎球菌病流行：使用新一代脑膜炎球菌结合疫苗进行高级预防和控制的案例。
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S274-S278. doi: 10.1093/infdis/jiz297.
7
Impact of vaccination on meningococcal epidemiology.疫苗接种对脑膜炎球菌流行病学的影响。
Hum Vaccin Immunother. 2016 Apr 2;12(4):1051-5. doi: 10.1080/21645515.2015.1108502. Epub 2015 Oct 29.
8
Serogroup B meningococcal vaccines from the public health perspective.从公共卫生角度看B群脑膜炎球菌疫苗
Lancet Infect Dis. 2023 Jan;23(1):13-14. doi: 10.1016/S1473-3099(22)00444-3. Epub 2022 Sep 7.
9
[Group B meningococcal invasive infections: an unresolved public health problem].[B 群脑膜炎球菌侵袭性感染：一个尚未解决的公共卫生问题]
Rev Med Suisse. 2011 Feb 23;7(283):447-50.
10
The threat of meningococcal disease during the Hajj and Umrah mass gatherings: A comprehensive review.朝觐和副朝期间脑膜炎球菌病的威胁：全面审查。
Travel Med Infect Dis. 2018 Jul-Aug;24:51-58. doi: 10.1016/j.tmaid.2018.05.003. Epub 2018 May 8.
引用本文的文献
1
Invasive Meningococcal Disease in the Vaccine Era.疫苗时代的侵袭性脑膜炎球菌病
Front Pediatr. 2018 Nov 9;6:321. doi: 10.3389/fped.2018.00321. eCollection 2018.
2
Costs of Invasive Meningococcal Disease: A Global Systematic Review.侵袭性脑膜炎球菌病的成本：全球系统评价。
Pharmacoeconomics. 2018 Oct;36(10):1201-1222. doi: 10.1007/s40273-018-0679-5.
3
An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate.基于无细胞酶的高效全合成脑膜炎球菌疫苗候选物。
NPJ Vaccines. 2016 Nov 15;1:16017. doi: 10.1038/npjvaccines.2016.17. eCollection 2016.
4
Issues in pediatric vaccine-preventable diseases in low- to middle-income countries.低收入和中等收入国家的儿童疫苗可预防疾病问题
Hum Vaccin Immunother. 2016 Sep;12(9):2365-77. doi: 10.1080/21645515.2016.1181243. Epub 2016 Jun 20.
5
Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles.降低补体抑制剂结合对天然脑膜炎奈瑟菌外膜囊泡免疫原性的影响
PLoS One. 2016 Feb 12;11(2):e0148840. doi: 10.1371/journal.pone.0148840. eCollection 2016.
6
The capsule polymerase CslB of Neisseria meningitidis serogroup L catalyzes the synthesis of a complex trimeric repeating unit comprising glycosidic and phosphodiester linkages.脑膜炎奈瑟菌L群的荚膜聚合酶CslB催化合成一种包含糖苷键和磷酸二酯键的复杂三聚体重复单元。
J Biol Chem. 2015 Oct 2;290(40):24355-66. doi: 10.1074/jbc.M115.678094. Epub 2015 Aug 18.
7
Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.一种新型b型流感嗜血杆菌- A和C群脑膜炎奈瑟菌-破伤风类毒素结合疫苗在6个月至5岁健康中国儿童中的安全性和免疫原性。
Hum Vaccin Immunother. 2015;11(5):1120-8. doi: 10.1080/21645515.2015.1033592.
8
Identification and therapeutic potential of a vitronectin binding region of meningococcal msf.脑膜炎球菌msf的玻连蛋白结合区域的鉴定及其治疗潜力
PLoS One. 2015 Mar 31;10(3):e0124133. doi: 10.1371/journal.pone.0124133. eCollection 2015.
9
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.A、C、W-135和Y群脑膜炎球菌结合破伤风类毒素疫苗：一种预防侵袭性脑膜炎球菌病的新型结合疫苗。
Infect Drug Resist. 2014 Apr 3;7:85-99. doi: 10.2147/IDR.S36243. eCollection 2014.
10
Review of meningococcal vaccines with updates on immunization in adults.成人脑膜炎球菌疫苗综述及免疫接种最新情况
Hum Vaccin Immunother. 2014;10(4):995-1007. doi: 10.4161/hv.27739. Epub 2014 Feb 5.
本文引用的文献
1
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.根据不同免疫计划，与常规婴儿疫苗联合或不联合使用时重组 B 群脑膜炎球菌疫苗的免疫原性和耐受性：一项随机对照试验。
JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.
2
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.在智利健康青少年中，一种包含多种脑膜炎奈瑟菌 B 群（4CMenB）组份的疫苗的免疫原性和耐受性：一项 2b/3 期、随机、观察者盲、安慰剂对照研究。
Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18.
3
Neisseria meningitidis B vaccines.脑膜炎奈瑟菌 B 疫苗。
Expert Rev Vaccines. 2011 Sep;10(9):1337-51. doi: 10.1586/erv.11.103.
4
Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.二价因子H结合蛋白（fHBP）疫苗预防脑膜炎奈瑟菌C群疾病潜力的临床前证据。
Hum Vaccin. 2011 Jan-Feb;7 Suppl(Suppl):68-74. doi: 10.4161/hv.7.0.14564. Epub 2011 Jan 1.
5
A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.一项关于 B 群脑膜炎奈瑟球菌缺失 lpxL1 和 synX 、过表达因子 H 结合蛋白、两种 PorA 以及稳定 OpcA 表达的天然外膜囊泡疫苗的 1 期研究。
Vaccine. 2011 Feb 4;29(7):1413-20. doi: 10.1016/j.vaccine.2010.12.039. Epub 2011 Jan 1.
6
Meningococcal carriage by age: a systematic review and meta-analysis.年龄与脑膜炎奈瑟菌带菌率：系统评价与荟萃分析。
Lancet Infect Dis. 2010 Dec;10(12):853-61. doi: 10.1016/S1473-3099(10)70251-6. Epub 2010 Nov 11.
7
Reverse vaccinology: developing vaccines in the era of genomics.反向疫苗学：基因组学时代的疫苗开发。
Immunity. 2010 Oct 29;33(4):530-41. doi: 10.1016/j.immuni.2010.09.017.
8
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.定性和定量评估脑膜炎球菌抗原，以评估基于蛋白质的疫苗的潜在菌株覆盖范围。
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5. doi: 10.1073/pnas.1013758107. Epub 2010 Oct 20.
9
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.多中心、开放性、随机、对照二期临床试验，研究在婴儿期接种含和不含外膜囊泡的新型重组 B 群脑膜炎球菌疫苗的效果。
Clin Infect Dis. 2010 Nov 15;51(10):1127-37. doi: 10.1086/656741. Epub 2010 Oct 18.
10
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.脑膜炎奈瑟菌候选疫苗表面蛋白 A（NspA）与因子 H 结合，增强脑膜炎奈瑟菌对补体的抵抗力。
PLoS Pathog. 2010 Jul 29;6(7):e1001027. doi: 10.1371/journal.ppat.1001027.
Zotero 插件